2026 Q1 -tulosraportti
97 päivää sitten
‧34 min
25,063 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 päivää sitten · MuokattuMy Nordnet portfolio is without leverage except in Dicot Pharma TO-7, but was still up approx. 60 % as of June 2 with the stock then at approx. 3.40 at its highest after several good PMs including the Q1 report. I believe Tobii will rise again at the latest after the Q2 report on Aug 28. They are in multi-party negotiations regarding e.g. a possible acquisition etc. If CEO Fadi Pharaon stops being bearish (likely as user RoPr on the placera forum) I guess the price will reach a new annual high some time after the report, Maybe in September-October and ends up significantly down or peaks at least 7 kr this year ?TARGET PRICE CALCULATION TOBII 2026 Group OPEX was 160 Mkr Q1 excl. one-off write-down. Full-year OPEX 2028 should be approx. 640 Mkr where further savings effect and salary increases etc. cancel each other out. Revenues are assumed to stabilize in P&S at the level of 350 Mkr after continued decline. Revenues in Integrations are now assumed to amount to around 200 Mkr on an annual basis and in the order of 250 Mkr 2028 Autosense should be able to generate sales of around 450 Mkr in 2028, of which BMW accounts for a large majority Total sales Integrations + Autosense 700 Mkr Total group sales assumed for 2028 = (P&S 350 + Integration 250 + Autosense 450) Mkr = 1050 Mkr Gross margin 90 % gives gross profit 945 Mkr 2028 OPEX is assumed to increase to 700 Mkr This gives EBIT 245 Mkr 2028, after standard tax approx. 195 Mkr. The number of shares is assumed to have increased via a directed issue to 260 Mkr. This gives earnings per share 0.75 Kr. P/E 20-25 gives a target price of 13 to 17 kr 2028 after deduction of net debt 2 kr per share. Return requirement 15 % per year gives a target price 2026 of approx. 10 to 13 kr. The full Tobii analysis : https://lnkd.in/gk_AVxFB
·15.7.Worst in class!Automatic technical analysis. Medium term, 10 Aug 2026 Tobii has broken the rising trend channel in the medium term, which initially indicates a weaker rate of ascent. The stock has broken a short-term resistance level and given a buy signal from a short-term trading range. The stock has marginally broken up through the resistance at approximately 1.70 kronor. An established break will indicate further upside.- 3.7.Regarding Autism Tobii secures design win for Get Set Early - delivers eyetracking for autism diagnostics 2026-02-11 The eyetracking-based screening tool for Autism Spectrum Disorder aims to enable earlier diagnosis and treatment through scientifically designed tests. Tobii, the global leader in eyetracking and pioneer in attention computing, has secured a design win for Get Set Early – a screening tool for Autism Spectrum Disorder (ASD) developed to identify early signs of autism in children as young as 12 months. The screening tool was developed by psychology professor Dr. Karen Pierce and her team at the University of California San Diego, and further developed by Butterfly Learnings. It is the first tool of its kind in India to have received CDSO certification and been approved for clinical use. Early detection crucial for effective treatment Research shows that children diagnosed with autism before the age of two exhibit better linguistic, cognitive, and social development. The brain is most malleable during the first years of life, making early detection crucial for effective treatment. Get Set Early enables early identification through a non-invasive test where the child watches a short video while the system records eye movements to measure how long the child focuses on different types of stimuli. The test generates objective biomarkers for autism spectrum disorder, making the assessment reliable and unbiased. The method is patented, scientifically validated, and based on the analysis of eye movements to detect signs of autism in children. It was developed by Dr. Karen Pierce, Associate Director of the Autism Center of Excellence at the University of California, San Diego. "Through the collaboration with Tobii, we can offer high-quality eyetracking diagnostics for early autism screening in India and global markets. This is an important step forward in our mission to make high-quality, technology-driven screening accessible to all children, everywhere. We look forward to scaling this partnership globally," says Abhishek Sen, co-founder and CEO of Butterfly Learnings. Eyetracking enabled by Tobii Eye Tracker 5L Tobii provides Butterfly Learnings with Tobii Eye Tracker 5L for integration into the Get Set Early screening tool. Tobii Eye Tracker 5L is a high-performance eyetracker developed for easy integration into digital health platforms, diagnostic tools, and other cognitive assessment products. "It is an honor for Tobii to be part of a product that can truly make a difference in people's lives. We are deeply impressed by what Butterfly Learnings has achieved with Get Set Early, where fundamental research insights have been transformed into clinical use that is approved, accessible, and scalable," says Emma Bauer, Senior Vice President, Integrations, at Tobii. The Get Set Early screening tool is now being implemented in clinics across India. In the development and integration of Tobii's eyetracking technology into the tool, Butterfly Learnings and Tobii have collaborated with Tiden Technologies, Tobii's Indian reseller specializing in research-grade neuroscience technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
97 päivää sitten
‧34 min
25,063 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sitten · MuokattuMy Nordnet portfolio is without leverage except in Dicot Pharma TO-7, but was still up approx. 60 % as of June 2 with the stock then at approx. 3.40 at its highest after several good PMs including the Q1 report. I believe Tobii will rise again at the latest after the Q2 report on Aug 28. They are in multi-party negotiations regarding e.g. a possible acquisition etc. If CEO Fadi Pharaon stops being bearish (likely as user RoPr on the placera forum) I guess the price will reach a new annual high some time after the report, Maybe in September-October and ends up significantly down or peaks at least 7 kr this year ?TARGET PRICE CALCULATION TOBII 2026 Group OPEX was 160 Mkr Q1 excl. one-off write-down. Full-year OPEX 2028 should be approx. 640 Mkr where further savings effect and salary increases etc. cancel each other out. Revenues are assumed to stabilize in P&S at the level of 350 Mkr after continued decline. Revenues in Integrations are now assumed to amount to around 200 Mkr on an annual basis and in the order of 250 Mkr 2028 Autosense should be able to generate sales of around 450 Mkr in 2028, of which BMW accounts for a large majority Total sales Integrations + Autosense 700 Mkr Total group sales assumed for 2028 = (P&S 350 + Integration 250 + Autosense 450) Mkr = 1050 Mkr Gross margin 90 % gives gross profit 945 Mkr 2028 OPEX is assumed to increase to 700 Mkr This gives EBIT 245 Mkr 2028, after standard tax approx. 195 Mkr. The number of shares is assumed to have increased via a directed issue to 260 Mkr. This gives earnings per share 0.75 Kr. P/E 20-25 gives a target price of 13 to 17 kr 2028 after deduction of net debt 2 kr per share. Return requirement 15 % per year gives a target price 2026 of approx. 10 to 13 kr. The full Tobii analysis : https://lnkd.in/gk_AVxFB
- ·15.7.Worst in class!Automatic technical analysis. Medium term, 10 Aug 2026 Tobii has broken the rising trend channel in the medium term, which initially indicates a weaker rate of ascent. The stock has broken a short-term resistance level and given a buy signal from a short-term trading range. The stock has marginally broken up through the resistance at approximately 1.70 kronor. An established break will indicate further upside.
- 3.7.Regarding Autism Tobii secures design win for Get Set Early - delivers eyetracking for autism diagnostics 2026-02-11 The eyetracking-based screening tool for Autism Spectrum Disorder aims to enable earlier diagnosis and treatment through scientifically designed tests. Tobii, the global leader in eyetracking and pioneer in attention computing, has secured a design win for Get Set Early – a screening tool for Autism Spectrum Disorder (ASD) developed to identify early signs of autism in children as young as 12 months. The screening tool was developed by psychology professor Dr. Karen Pierce and her team at the University of California San Diego, and further developed by Butterfly Learnings. It is the first tool of its kind in India to have received CDSO certification and been approved for clinical use. Early detection crucial for effective treatment Research shows that children diagnosed with autism before the age of two exhibit better linguistic, cognitive, and social development. The brain is most malleable during the first years of life, making early detection crucial for effective treatment. Get Set Early enables early identification through a non-invasive test where the child watches a short video while the system records eye movements to measure how long the child focuses on different types of stimuli. The test generates objective biomarkers for autism spectrum disorder, making the assessment reliable and unbiased. The method is patented, scientifically validated, and based on the analysis of eye movements to detect signs of autism in children. It was developed by Dr. Karen Pierce, Associate Director of the Autism Center of Excellence at the University of California, San Diego. "Through the collaboration with Tobii, we can offer high-quality eyetracking diagnostics for early autism screening in India and global markets. This is an important step forward in our mission to make high-quality, technology-driven screening accessible to all children, everywhere. We look forward to scaling this partnership globally," says Abhishek Sen, co-founder and CEO of Butterfly Learnings. Eyetracking enabled by Tobii Eye Tracker 5L Tobii provides Butterfly Learnings with Tobii Eye Tracker 5L for integration into the Get Set Early screening tool. Tobii Eye Tracker 5L is a high-performance eyetracker developed for easy integration into digital health platforms, diagnostic tools, and other cognitive assessment products. "It is an honor for Tobii to be part of a product that can truly make a difference in people's lives. We are deeply impressed by what Butterfly Learnings has achieved with Get Set Early, where fundamental research insights have been transformed into clinical use that is approved, accessible, and scalable," says Emma Bauer, Senior Vice President, Integrations, at Tobii. The Get Set Early screening tool is now being implemented in clinics across India. In the development and integration of Tobii's eyetracking technology into the tool, Butterfly Learnings and Tobii have collaborated with Tiden Technologies, Tobii's Indian reseller specializing in research-grade neuroscience technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2026 Q1 -tulosraportti
97 päivää sitten
‧34 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 29.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
25,063 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sitten · MuokattuMy Nordnet portfolio is without leverage except in Dicot Pharma TO-7, but was still up approx. 60 % as of June 2 with the stock then at approx. 3.40 at its highest after several good PMs including the Q1 report. I believe Tobii will rise again at the latest after the Q2 report on Aug 28. They are in multi-party negotiations regarding e.g. a possible acquisition etc. If CEO Fadi Pharaon stops being bearish (likely as user RoPr on the placera forum) I guess the price will reach a new annual high some time after the report, Maybe in September-October and ends up significantly down or peaks at least 7 kr this year ?TARGET PRICE CALCULATION TOBII 2026 Group OPEX was 160 Mkr Q1 excl. one-off write-down. Full-year OPEX 2028 should be approx. 640 Mkr where further savings effect and salary increases etc. cancel each other out. Revenues are assumed to stabilize in P&S at the level of 350 Mkr after continued decline. Revenues in Integrations are now assumed to amount to around 200 Mkr on an annual basis and in the order of 250 Mkr 2028 Autosense should be able to generate sales of around 450 Mkr in 2028, of which BMW accounts for a large majority Total sales Integrations + Autosense 700 Mkr Total group sales assumed for 2028 = (P&S 350 + Integration 250 + Autosense 450) Mkr = 1050 Mkr Gross margin 90 % gives gross profit 945 Mkr 2028 OPEX is assumed to increase to 700 Mkr This gives EBIT 245 Mkr 2028, after standard tax approx. 195 Mkr. The number of shares is assumed to have increased via a directed issue to 260 Mkr. This gives earnings per share 0.75 Kr. P/E 20-25 gives a target price of 13 to 17 kr 2028 after deduction of net debt 2 kr per share. Return requirement 15 % per year gives a target price 2026 of approx. 10 to 13 kr. The full Tobii analysis : https://lnkd.in/gk_AVxFB
- ·15.7.Worst in class!Automatic technical analysis. Medium term, 10 Aug 2026 Tobii has broken the rising trend channel in the medium term, which initially indicates a weaker rate of ascent. The stock has broken a short-term resistance level and given a buy signal from a short-term trading range. The stock has marginally broken up through the resistance at approximately 1.70 kronor. An established break will indicate further upside.
- 3.7.Regarding Autism Tobii secures design win for Get Set Early - delivers eyetracking for autism diagnostics 2026-02-11 The eyetracking-based screening tool for Autism Spectrum Disorder aims to enable earlier diagnosis and treatment through scientifically designed tests. Tobii, the global leader in eyetracking and pioneer in attention computing, has secured a design win for Get Set Early – a screening tool for Autism Spectrum Disorder (ASD) developed to identify early signs of autism in children as young as 12 months. The screening tool was developed by psychology professor Dr. Karen Pierce and her team at the University of California San Diego, and further developed by Butterfly Learnings. It is the first tool of its kind in India to have received CDSO certification and been approved for clinical use. Early detection crucial for effective treatment Research shows that children diagnosed with autism before the age of two exhibit better linguistic, cognitive, and social development. The brain is most malleable during the first years of life, making early detection crucial for effective treatment. Get Set Early enables early identification through a non-invasive test where the child watches a short video while the system records eye movements to measure how long the child focuses on different types of stimuli. The test generates objective biomarkers for autism spectrum disorder, making the assessment reliable and unbiased. The method is patented, scientifically validated, and based on the analysis of eye movements to detect signs of autism in children. It was developed by Dr. Karen Pierce, Associate Director of the Autism Center of Excellence at the University of California, San Diego. "Through the collaboration with Tobii, we can offer high-quality eyetracking diagnostics for early autism screening in India and global markets. This is an important step forward in our mission to make high-quality, technology-driven screening accessible to all children, everywhere. We look forward to scaling this partnership globally," says Abhishek Sen, co-founder and CEO of Butterfly Learnings. Eyetracking enabled by Tobii Eye Tracker 5L Tobii provides Butterfly Learnings with Tobii Eye Tracker 5L for integration into the Get Set Early screening tool. Tobii Eye Tracker 5L is a high-performance eyetracker developed for easy integration into digital health platforms, diagnostic tools, and other cognitive assessment products. "It is an honor for Tobii to be part of a product that can truly make a difference in people's lives. We are deeply impressed by what Butterfly Learnings has achieved with Get Set Early, where fundamental research insights have been transformed into clinical use that is approved, accessible, and scalable," says Emma Bauer, Senior Vice President, Integrations, at Tobii. The Get Set Early screening tool is now being implemented in clinics across India. In the development and integration of Tobii's eyetracking technology into the tool, Butterfly Learnings and Tobii have collaborated with Tiden Technologies, Tobii's Indian reseller specializing in research-grade neuroscience technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt